A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$59.40
0.00%
(0.00) 1D
Oct 15, 9:31:36 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1LN34...
Open
R$58.26
High
R$59.40
Low
R$58.26
Mkt. cap
31.32B
Avg. vol.
440.00
Volume
0.00
52-wk high
R$132.40
52-wk low
R$50.25
Shares outstanding
133.81M
No. of employees
2K
Open
R$58.26
High
R$59.40
Low
R$58.26
Mkt. cap
31.32B
Avg. vol.
440.00
Volume
0.00
52-wk high
R$132.40
52-wk low
R$50.25
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
ad-hoc-news.de
·
5 hours ago
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Alnylam
·
12 hours ago
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
BioSpace
·
1 day ago
Alnylam bulls and bears fight it out after business-shaking guidance cut
The Globe and Mail
·
2 weeks ago
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals Inc Bdr